Other biomarkers, such as human epidermal growth factor receptor-2 (HER2)37–47, estrogen receptor39,48–50, prostate-specific membrane antigen51–53, folate receptor54–56, and survivin57, have been described as CTCs markers in different cancers, with different clinical significance. Here, ERBB2 is linked to cancer.